Home Page
About us
Guangzhou KOFA Biotechnology Co.,Ltd. was founded in 2004, headquartered in Guangzhou High-tech Industry Development Zone, Science City. It is a national high-tech enterprise focusing on the research and development, manufacturing, sales and service of in vitro diagnostic reagents and instruments (IVD). The company has always adhered to the strategy of independent intellectual property rights, independent innovation and independent brand, and has established a biochemical immunoassay assembly line platform, a chemiluminescence detection platform, a fluorescent immunochromatography platform, and a biochemical diagnostic technology platform. It has obtained more than 200 registration certificates, and its detection series covers liver and kidney function, cardiovascular disease, blood lipids, diabetes, genetic diseases, tumors, thyroid function and other fields, and is widely used in medical institutions and third-party testing centers at all levels across the country.
News Center
Compared with traditional IVD products, POCT has three major advantages: short test time, wide detection space, and easy operation. It can meet the needs of fast and timely testing, and has become a revolutionary and rapidly developing sub field in the IV
More+Products
Service Support
KOFA has always upheld the philosophy of “Technology Benefiting All” and has remained steadfast in its commitment to delivering high-quality products and exceptional technical services to customers over the years. Backed by a strong technical support team, we provide professional product consultation, reagent optimization, and comprehensive after-sales services to promptly address any technical issues our customers may encounter during product use.
Contact us
2024-12-10 Kefang News
On November 28, 2024, the Jiangxi Provincial Medical Security Bureau issued the "Notice on the Proposed Winning Results of the Inter-provincial Alliance Centralized Volume Procurement of Biochemical Testing Reagents such as Glycometabolism".
According to the data of the proposed winning results, a total of 155 manufacturers and 2,314 specifications were selected for this volume-based procurement. Among them, 21 projects and 42 specifications submitted by KOFA Bio were all successfully selected, and all of the capacity groups were included in Group A, becoming the focus of this centralized procurement.
In this centralized procurement, KOFA Bio stood out in the fierce market competition with its excellent product quality and significant market competitiveness. KOFA Bio will continue to strengthen its R&D capabilities, continuously optimize and expand its product lines to accurately meet the diversified needs of the market. KOFA Bio will create significant value for customers through continuous technological innovation and excellent customer service, and achieve a win-win situation for the company and society with forward-looking scientific research investment and high-quality product output!